COMMUNIQUÉS West-GlobeNewswire

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
06/02/2026
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001) All [...]
VALNEVA Declaration of shares and voting rights: January 31, 2026
06/02/2026
VALNEVA Declaration of shares and voting rights January 31, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint-Joseph [...]
HUTCHMED to Announce 2025 Final Results
06/02/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, [...]
VALNEVA Déclaration d’actions et de droits de vote : 31 janvier 2026
06/02/2026
VALNEVA Déclaration d’actions et de droits de vote 31 janvier 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : Îlot [...]
Chiral raises $12M to unlock post-silicon computing beyond Moore’s Law
06/02/2026
ZURICH, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Chiral , a Swiss nanotechnology company pioneering next-generation semiconductor and quantum technologies with nanomaterials, today announced the successful closing of a $12 [...]
Coloplast A/S - Interim Financial Report, Q1 2025/26
06/02/2026
2025/26 Interim financial results, Q1 2025/26 1 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth 1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%- [...]
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
06/02/2026
Allschwil, Switzerland – February 06, 2026 Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker and renal findings [...]
Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026
06/02/2026
An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth eligibility considerations, [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
05/02/2026
CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
05/02/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
05/02/2026
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 janvier 2026
05/02/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 janvier 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
05/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
05/02/2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46 th [...]
His Choice Health Announces Opening of New Charlotte Clinic, Expanding Access to Trusted, Patient-Centered Men’s Health Care
06/02/2026
Regional Growth Following Raleigh–Durham Brand Unification CHARLOTTE, NC, Feb. 05, 2026 (GLOBE NEWSWIRE) -- His Choice Health today announced the upcoming opening of its newest clinic in Charlotte, targeted late [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
05/02/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
05/02/2026
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Renaissance Recovery’s Award-Winning Drug and Alcohol Rehab Center Launches New 10,000 Sq. Ft. Expansion in Nashville, Tennessee
05/02/2026
NASHVILLE, Tenn., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Renaissance Recovery, a District Behavioral Health Group (DBH) company, announced today the opening of its newest expansion in Nashville, Tennessee. As an award- [...]
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
05/02/2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial [...]

Pages